Read Why Eloxx Pharma Stock Continues To Fall

by Vandana Singh, Benzinga Editor

November 18, 2021 2:12 PM | 1 min read | Make a Comment

H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc ELOX to $1 from $2 and reiterated a Neutral rating.
Analyst Andrew Fein says the ELX-02 top-line data "raises more questions than answers."
Despite the "seemingly positive narrative put forward for the top-line data from ELX-02's Phase 2 top-line readout, we remain unconvinced," Fein tells investors in a research note.
Related Link: Eloxx Shares Slump As Phase 2 Cystic Fibrosis Trial Data Fails To Cheer Investors.
Price Action: ELOX shares are down 12.40% at $0.76 during the market session on the last check Thursday.